Emerging Vaccines – Landscape & Forecast – Disease Landscape & Forecast (G7)

Vaccination programs have had a revolutionary impact on global public health, not only dramatically reducing the incidence of infectious disease but also reducing childhood and adult mortality and improving the quality of life worldwide. Individuals can receive a wide range of vaccinations throughout their lives to prevent infections and diseases associated with long-term chronic disorders. Given the significant advances in vaccine technologies such as mRNA-based vaccines, commercial opportunity exists for robust and diverse vaccines that can offer meaningful advantages over current agents. Both the adult and pediatric segments of the vaccine market remain attractive for the development of new prophylactic options. This content includes coverage of key infectious diseases such as human papillomavirus (HPV), herpes zoster virus (HZ), hepatitis B virus (HBV), meningococcus, pneumococcus, seasonal influenza, respiratory syncytial virus (RSV), and COVID-19. Key vaccines and major market players include Pfizer (Comirnaty, Prevnar 13), GSK (Shingrix, Menveo, Arexvy), Sanofi (Fluzone, MenQuadfi), Merck (Gardasil, Pneumovax 23), and Moderna (Spikevax).

Questions answered

• What are the sizes of the populations eligible for key vaccination programs in the G7?
• What are the key drivers of brand preference in each vaccine market?
• How will the current vaccine pipeline fulfill areas of unmet need?
• How will key current and emerging vaccines perform commercially?
• In the aftermath of the COVID-19 pandemic, how has the use of current vaccines evolved?

Geographies: United States, EU5, Japan

Primary research: Country-specific interviews with thought-leading infectious disease specialists. Survey data collected for this and other Clarivate research

Epidemiology: Vaccine-eligible pool by country, segmented by key infectious diseases (HPV, HZ, HBV, meningococcus, pneumococcus, seasonal influenza, RSV, and COVID-19)

Forecast: 10-year, annualized, drug-level sales and patient share of key vaccines through 2034, segmented by brands / generics and epidemiological subpopulations

Drug treatments: Coverage of key current and emerging therapies

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.